Skip to content

The AMD Experts


Our Team

The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence.

Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.

Latest News & Upcoming Events

View More
Article: March 2018 | Primary Care Optometry News

Treat AMD at First Detection

Laurie Sorrenson, OD, discusses early AMD treatment in Primary Care Optometry News.

Press Releases: April 11, 2018

AdaptDx Used in EU Study

AdaptDx® has been selected as a functional testing device in the MACUSTAR project, a 5-year study to explore AMD.

Article: February 1, 2019 | Optometric Management

Roll Out New Technology to the Staff

By implementing these five steps, you have an great chance of successfully adding new equipment to your practice as our Practice Management Consultant, Shelly Reil knows very well.

The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.

Dr. Shawn Lewis1 Shawn Lewis, MD View all testimonials

Put Our Expertise to Work

Testing with AdaptDx

AdaptDx identifies impaired Dark Adaptation™—the earliest warning sign of AMD.

Guiding AdaptDx Implementation

Each AdaptDx purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.